System Of Automatically Monitoring Electronic Billboard To Immediately Responding Production Abnormality And Method Thereof

A system of automatically monitoring an electronic billboard to immediately responding a production abnormality and a method thereof are disclosed. In the system, a monitoring device performs an image pattern analysis on a monitoring image to analyze at least one analysis area, and captures the at least one analysis area as a to-be-analyzed image; at least one image analysis method is set to transform the to-be-analyzed image into an image characteristic according to an image pattern of the to-be-analyzed image. When a comparison between the image characteristic and a preset characteristic indicates an abnormality, a monitoring device generates, records and transmits a warning message and/or issues an alarm, thereby achieving the technical effect of automatically monitoring the electronic billboard and immediately responding a production abnormality.

DEVICE FOR SAVING POWER CONSUMPTION OF HEATING AND AIR CONDITIONING SYSTEM

A device for saving power consumption of heating and air conditioning system is provided. The energy saving device is adapted to automatically stop an air conditioner when outdoor temperature is lower than a set temperature or automatically stop a heater when outdoor temperature is higher than a set temperature. The energy saving device is provided with an outdoor temperature sensor and converter for measuring an outdoor temperature and converting the measured temperature into a first voltage value, a conversion circuit for converting a set temperature of stopping the air conditioner/heater into a second voltage value, a control circuit for controlling the air conditioner/heater, and a comparison circuit for comparing the first voltage value with the second voltage value and transmitting the result to the control circuit.

Antagonism of the VIP signaling pathway

Inhibition of the VIP signaling pathway using VIP antagonists is contemplated. Methods of treating or preventing a viral infection comprising administering a VIP antagonist to a subject in need thereof are also contemplated.

Injection mold

An injection mold for molding a product which has an inclined groove and a straight gap at a side thereof includes a female mold and a male mold. The female mold includes a female core and an inclined pillar mounted in the female mold. The male mold includes a male core, a first sliding block and a second sliding block. The first sliding block is slidably mounted on the male mold, and has an inclined guiding surface. The second sliding block is slidably mounted on the inclined guiding surface. When the injection mold is opened, the second sliding block is smoothly parted from the product along the inclined guiding surface to form the inclined groove, and then, the first sliding block is parted from the product to form the straight gap under the action of the inclined pillar.

Test Time Estimation Suggestion Providing System Based On Product Configuration Information And Method Thereof

A test time estimation suggestion providing system based on product configuration information and a method thereof are disclosed. In the system, a database, a product configuration word database and a product embedding vector database are established, new product configuration information is analyzed to obtain analysis words, one-hots corresponding to the analysis words are queried and imported into a trained word2vec neural network model to calculate word embedding vectors, and all word embedding vectors are added to obtain a new product embedding vector, which is then compared with the existing product embedding vectors to find the product embedding vector most approximate to the new product embedding vector, and a model test time and a family test time of the existing product corresponding to the found product embedding vector are used as an estimation suggestion for a model test time and a family test time of the new product.

Methods of treating cancer using cell based therapies

This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signaling and/or inhibiting phosphatidylinositol-3-kinase (PI3 kinase) inhibitor signaling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signaling, a VIP degrading enzyme, and combinations thereof.

Methods of Treating Cancer and Infectious Diseases Using Cell Based Therapies

This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signaling and/or inhibiting phosphatidylinositol-3-kinase (PI3 kinase) inhibitor signaling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signaling, a VIP degrading enzyme, and combinations thereof. 1. An in vitro cell culture composition comprising purified T cells and a VIP receptor antagonist and anti-CD3 antibodies and anti-CD28 antibodies optionally immobilized on a bead or solid surface.2. The composition of claim 1 , wherein more than 15% of the T cells are negative for CD28.4. An in vitro cell culture composition comprising purified T cells and a VIP degrading enzyme and anti-CD3 antibodies and anti-CD28 antibodies optionally immobilized on a bead or solid surface.5. The composition of claim 4 , wherein more than 15% of the T cells are negative for CD28.8. An in vitro cell culture composition comprising purified T cells and a phosphatidylinositol-3-kinase inhibitor and anti-CD3 antibodies and anti-CD28 antibodies optionally immobilized on a bead or solid surface.9. The composition of claim 8 , wherein more than 15% of the T cells are negative for CD28.10. The composition of claim 9 , wherein the phosphatidylinositol-3-kinase inhibitor is selected from idelalisib.11. A method of proliferating T cells that are negative for CD28 using an in vitro cell culture as provided in providing replicated T cells.12. The method of claim 11 , wherein the replicated T cells have increased expression of CD28 compared with levels prior to replication.13 ...

Antagonism of the VIP Signaling Pathway

Inhibition of the VIP signaling pathway with VIP antagonist is contemplated. In certain embodiments, the disclosure relates to methods of enhancing the immune response to a cell therapy comprising administering a VIP antagonist to a subject in combination with a cell. In certain embodiments, the subject is diagnosed with leukemia or lymphoma. In certain embodiments, the cell is a blood cell, bone marrow cell, leukocyte, T-cell, natural killer cell, a hematopoietic stem cell, a G-CSF mobilized or non-mobilized blood mononuclear cell. 1. A method of treating a subject diagnosed with cancer comprising administering a cell in combination with a VIP antagonist to a subject in need thereof.2. The method of claim 1 , wherein the subject is diagnosed with leukemia3. The method of claim 1 , wherein the subject is diagnosed with lymphoma.4. The method of claim 1 , wherein the cell is a blood mononuclear cell.5. The method of claim 1 , wherein the cell is a bone marrow cell.6. The method of claim 1 , wherein the cell is a leukocyte.7. The method of claim 1 , wherein the cell is a T-cell.8. The method of claim 1 , wherein the cell is a natural killer cell.9. The method of claim 1 , wherein the cell is a hematopoietic stem cell.10. The method of claim 1 , wherein the cell is a G-CSF mobilized blood mononuclear cell.11. The method of claim 1 , wherein the cell is an HLA matched or mis-matched allogeneic cell.12. The method of claim 1 , wherein the cell is syngeneic cell.13. The method of claim 1 , wherein the cell is an autologous cell.14. The method of claim 1 , wherein the VIP antagonist is a peptide having a C-terminal amide and is optionally modified with hydrocarbon or polyethylene glycol groups and wherein the peptide has SEQ ID NO: 9 claim 1 , wherein X is M.15. A method of treating leukemia comprising administering a VIP antagonist to a subject in combination with transplanting hematopoietic stem cells.16. The method of claim 15 , wherein the VIP antagonist is a peptide ...

Antagonism of the VIP signaling pathway

Inhibition of the VIP signaling pathway with VIP antagonist is contemplated. In certain embodiments, the disclosure relates to methods of enhancing the immune response to a cell therapy comprising administering a VIP antagonist to a subject in combination with a cell. In certain embodiments, the subject is diagnosed with leukemia or lymphoma. In certain embodiments, the cell is a blood cell, bone marrow cell, leukocyte, T-cell, natural killer cell, a hematopoietic stem cell, a G-CSF mobilized or non-mobilized blood mononuclear cell.

ANTAGONISM OF THE VIP SIGNALING PATHWAY

The disclosure relates to inhibition of the VIP signaling pathway. In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering a VIP antagonist to a subject in need thereof. 1. A method of treating or preventing a viral infection comprising administering a VIP antagonist to a subject in need thereof.2. The method of claim 1 , wherein the subject is immune compromised.3. The method of claim 1 , wherein the subject is a transplant recipient.4. The method of claim 1 , wherein the viral infection is a virus selected from the group consisting of an influenza A virus including subtype H1N1 claim 1 , influenza B virus claim 1 , influenza C virus claim 1 , rotavirus A claim 1 , rotavirus B claim 1 , rotavirus C claim 1 , rotavirus D claim 1 , rotavirus E claim 1 , SARS coronavirus claim 1 , human adenovirus types (HAdV-1 to 55) claim 1 , human papillomavirus (HPV) Types 16 claim 1 , 18 claim 1 , 31 claim 1 , 33 claim 1 , 35 claim 1 , 39 claim 1 , 45 claim 1 , 51 claim 1 , 52 claim 1 , 56 claim 1 , 58 claim 1 , 59 claim 1 , parvovirus B19 claim 1 , molluscum contagiosum virus claim 1 , JC virus (JCV) claim 1 , BK virus claim 1 , Merkel cell polyomavirus claim 1 , coxsackie A virus claim 1 , norovirus claim 1 , Rubella virus claim 1 , lymphocytic choriomeningitis virus (LCMV) claim 1 , yellow fever virus claim 1 , measles virus claim 1 , mumps virus claim 1 , respiratory syncytial virus claim 1 , rinderpest virus claim 1 , California encephalitis virus claim 1 , hantavirus claim 1 , rabies virus claim 1 , ebola virus claim 1 , marburg virus claim 1 , herpes simplex virus-1 (HSV-1) claim 1 , herpes simplex virus-2 (HSV-2) claim 1 , varicella zoster virus (VZV) claim 1 , Epstein-Barr virus (EBV) claim 1 , cytomegalovirus (CMV) claim 1 , herpes lymphotropic virus claim 1 , roseolovirus claim 1 , Kaposi's sarcoma-associated herpesvirus claim 1 , hepatitis A (HAV) claim 1 , hepatitis B (HBV) claim 1 , hepatitis C ( ...

MOLD HAVING SLIDE

A mold having slide is disclosed, including an upper mold plate, a lower mold plate mating with the upper mold plate, a slanted guide post, a slide, and a locating mechanism. The slanted guide post is mounted on the upper mold plate. The slide and the locating mechanism are both mounted on the lower mold plate. The locating mechanism has a locating stop. The locating stop is fixed to the lower mold plate. The locating stop has a pull rod movably mounted thereto with one end of the pull rod fixed to the slide. A compression spring is located between an opposite end of the pull rod and the locating stop. The mold can effectively prevent the slide from undesired move-back and thus being incorrectly positioned so as to eliminate the potential risk of damage of the mold by the slanted guide post. 1. A mold , comprising:an upper mold plate;at least one slanted guide post, which is mounted on the upper mold plate;a lower mold plate, which is mating with the upper mold plate;at least one slide, which is movably mounted on the lower mold plate; anda locating mechanism, which is mounted on the lower mold plate and comprises a locating stop, which is fixed on the lower mold plate and comprises a pull pod movably mounted thereto, the pull pod having an end fixed to the slide and an opposite end supporting a compression spring with respect to the locating stop.2. The mold as claimed in claim 1 , wherein the locating mechanism comprises a compression spring protecting cover which is fixed on the locating stop and encloses the compression spring. 1. Field of the InventionThe present invention generally relates to a mold, and in particular to a mold having a slide.2. The Related ArtsReference is now made to of the attached drawings, which shows a conventional mold ′. The mold ′ comprises an upper mold plate ′, a lower mold plate ′, a slide ′ which is slidably mounted on the lower mold plate ′, a slanted guide post ′, and a locating pin ′. The slide ′ forms a guide groove (not ...

INJECTION MOLD FORMING A PRODUCT HAVING A BARBED STRUCTURE

A mold for making a product having a barbed structure at an intermediate position thereof has a stationary mold including a fixing board, a mold board, a core, an oblique block, a limiting element, and an elastic element. The mold board has a trough and a limiting chute. The core has a cavity and a slide chute. The oblique block having a hole communicating the cavity is movably disposed in the slide chute. An end of the block is extendable out of the cavity and an opposite end forms an accommodating hole. The limiting element includes a limiting end extending into the accommodating hole and a fixing end movably disposed in the limiting chute. The elastic element of which one end is against the accommodating hole and an opposite end is set against the trough is disposed in the accommodating hole. 1. A mold adapted to mold a product having an intermediate portion that forms a barbed structure , the mold comprising a stationary mold section and a movable mold section , the stationary mold section comprising:a stationary mold fixing board;a stationary mold board mounted to the stationary mold fixing board, the stationary mold board forming an inclined extension trough and an inclined position limiting chute communicating the extending trough;a stationary mold core fixed inside the stationary mold board, the stationary mold core forming a stationary mold cavity, the stationary mold core forming an inclined slide chute having an end in communication with the stationary mold cavity;an oblique block movably disposed in the slide chute and having an end extendable out of the stationary mold cavity and an opposite end forming an accommodating hole, the oblique block having a molding hole communicating the stationary mold cavity;a position limiting element comprising a position limiting end and a fixing end connected the position limiting end, the fixing end being received the accommodating hole by extending through the position limiting chute and fastened to the oblique block ...

ASSEMBLING METHOD OF AN INJECTION MOLD

An assembling method of an injection mold includes the steps of: disposing guide rods and a ejection pin plate on a punch template; inserting guide bushes into the ejection pin plate; inserting ejection pins respectively into the ejection pin plate and the punch template; fastening a ejection pin fixing plate to the ejection pin plate; fastening a die fixing plate and spacer plates to the punch template, and inserting the other ends of the guide rods into the die fixing plate; and disposing a press plate into the die fixing plate, and fastening the guide rods to the die fixing plate by tightening screws. The assembling method set the guide rods first o achieve a positioning function before ejection pin plate is assembled, and thereby capable of effectively eliminating the problems of deformation of the ejection pin plate, breaking of the ejection pin, and abrasion occurring in the return stroke. 1. An assembling method of an injection mold , the injection mold comprising a movable die and a stationary die , the movable die comprising a movable die fixing plate , a plurality of spacer plates , an ejection pin plate , an ejection pin fixing plate , a punch template , a plurality of ejection pins , a plurality of guide rods , a press plate , and a plurality of guide bushes , the assembling method comprising steps of:(1) disposing the guide rods and the ejection pin plate on the punch template;(2) putting the guide bushes to encompass the guide rods and inserting the guide bushes into the ejection pin plate to be fastened therein;(3) inserting the ejection pins respectively into the ejection pin plate and the punch template;(4) fastening the ejection pin fixing plate to the ejection pin plate and inserting the guide bushes into the ejection pin fixing plate to be fastened therein;(5) fastening the movable die fixing plate and the spacer plates to the punch template, and inserting the other ends of the guide rods into the movable die fixing plate to be fastened therein; ...

SELF-ADJUSTING ANGLED EJECTOR

Provided is a self-adjusting angled ejector including an angled ejector base, a fixing member, an angled ejector pin and two adjusting plates. The angled ejector pin disposes an undercut-forming portion projecting on an upper end thereof. A lower end of the angled ejector pin is received in a groove of the angled ejector base and is detachably fixed on it. The two adjusting plates form a rotating region therebetween for pivotally positioning the angled ejector base. When ejecting the product, the angled ejector base can rotate to adjust the angle of the angled ejector pin for preventing the angled ejector pin from being bent or broken. Moreover, the mould need not be disassembled when mounting or dismounting the angled ejector pin, thereby saving the assembling or disassembling time of the mould, improving the production efficiency of the mould, and reducing the man power and material resources. 1. A self-adjusting angled ejector , comprising:an angled ejector base, disposing a groove on a top surface thereof;a fixing member;an angled ejector pin, disposing an undercut-forming portion projecting on an upper end thereof, wherein a lower end of the angled ejector pin is received in the groove and is detachably fixed on the angled ejector base by the fixing member; andtwo adjusting plates, being parallel to each other and forming a rotating region therebetween, wherein the angled ejector base is pivotally located on the rotating region.2. The self-adjusting angled ejector as claimed in claim 1 , wherein each one of the two adjusting plates disposes a pivot hole straightly facing the rotating region claim 1 , and the angled ejector base disposes two connecting posts claim 1 , which are separately protruding from two side surfaces thereof and are pivotally engaged with the pivot holes.3. The self-adjusting angled ejector as claimed in claim 2 , wherein the two connecting posts are cylindrical.4. The self-adjusting angled ejector as claimed in claim 1 , wherein the angled ...

SWITCHING WARE

Disclosed is a switching ware, employed in a mold having a cope plate, a middle template and a lower die. The switching ware comprises a trip lever, a trip limit element and at least one spring. The trip lever is installed on the cope plate. A trip limit controller is fixedly installed on the lower die and has a clipping plate formed in the middle of the trip lever. The trip limit element is slidably installed inside the open slot. The trip limit element can extend out of the open slot to reach against the clipping plate and the trip limit controller can push the trip limit element to slide in the open slot. The mold can complete the operation of closing mold in a specific sequence with the switching ware of the present invention. The structure of the switching ware is simple, safe, reliable and with low failure probability. 1. A switching ware , employed in a mold having a cope plate , a middle template and a lower die wherein the mold needs to be closed in a specific sequence and an open slot is opened on the middle template , comprising:a trip lever, installed on the cope plate, and having a clipping plate formed in the middle of the trip lever, and a trip limit controller is fixedly installed on the lower die and has a first sliding cant formed on the trip limit controller;a trip limit element, slidably installed inside the open slot and a second sliding cant is formed on the trip limit element; andat least one spring, installed between the middle template and the trip limit element, wherein the trip limit element can extend out of the open slot to reach against the clipping plate and the trip limit controller can push the trip limit element to slide in the open slot by moving the first sliding cant along the second sliding cant.2. The switching ware of claim 1 , wherein a middle template limiter is fixedly installed on the middle template and the middle template limiter comprises a restrict slot to allow the trip lever movably passing through the restrict slot. ...

Mold with sliders

Disclosed is a mold with sliders employed for molding a plastic product having a first lateral bulge and a second lateral bulge in different directions. The mold comprises a fixed half, an angle pin, a moving half, a main slider and a tilted slider. The angle pin comprises an angle pin body with two opposite forcing surfaces. The main slider comprises a tilted slide track corresponding to the second lateral bulge. A pin slot is formed on the main slider. Two weighted surfaces are formed on the main slider at the opposite two sides of the pin slot. The angle pin body can slidably dip into the pin slot and the driving guide slot. By acting on the tilted slider and then on the main slider with the angle pin body, the mold can respectively complete the procedure of pulling out laterally bulges aslant and horizontally.

PLASTIC INJECTION MOLD

A plastic injection mold includes a female mold, a male mold mateable with the female mold, and two ejection mechanisms. The ejection mechanisms are coupled to the ejector plate. Each ejection mechanism includes a slanted ejector lever and a hook portion projecting sideways from one end of the slanted ejector lever. When a product has hook like portions is molded with the injection mold, the slanted ejector levers are movable in both horizontal and vertical directions at the same time to help easily releasing the molded product from the mold thereby improving production efficiency. 1. An injection mold , comprising:a female mold;a male mold, which is mateable with the female mold, the male mold comprising a male mold platen, an ejector plate opposing the male mold platen, and a mold core disposed on the male mold platen, a slanted hole being defined in the mold core; andan ejection mechanism, which is coupled to the ejector plate, the ejection mechanism comprising a slanted ejector lever, which has one end forming a sideways projecting hook portion, the slanted ejector lever being slidably received in the slanted hole of the mold core and partially projecting out of the mold core, a molding cavity being defined by the hook portion and an end surface of the mold core for molding a hook portion of a product that is molded with the injection mold.2. The injection mold of claim 1 , wherein the mold core forms therein a receiving slot and a receiving hole communicating the receiving slot claim 1 , the receiving hole being in communication with the slanted hole claim 1 , and the slanted ejector lever being movably inserted into the receiving slot claim 1 , the receiving hole claim 1 , and the slanted hole.3. The injection mold of claim 1 , wherein the ejection mechanism comprises a vertical ejector lever claim 1 , one end of which is movably coupled to the slanted ejector lever and an opposite end is fixed on the ejector plate.4. The injection mold of claim 3 , wherein ...

INJECTION MOLD

An injection mold for molding a product which has an inclined groove and a straight gap at a side thereof includes a female mold and a male mold. The female mold includes a female core and an inclined pillar mounted in the female mold. The male mold includes a male core, a first sliding block and a second sliding block. The first sliding block is slidably mounted on the male mold, and has an inclined guiding surface. The second sliding block is slidably mounted on the inclined guiding surface. When the injection mold is opened, the second sliding block is smoothly parted from the product along the inclined guiding surface to form the inclined groove, and then, the first sliding block is parted from the product to form the straight gap under the action of the inclined pillar. 1. An injection mold for molding a product which has an inclined groove and a straight gap located at a side thereof and spaced from each other , comprising:a female mold including a female core mounted in a bottom of the female mold, and an inclined pillar slantwise mounted in the female mold with a bottom end thereof stretching under the female mold; anda male mold positioned under the female mold when the injection mold is closed, one side of a top of the male mold defining a receiving space, the male mold including:a male core mounted in the top of the male mold and spaced from the receiving space, and having a top thereof spaced from a bottom of the female core to define a shaping cavity therebetween for molding the product;a first sliding block slidably mounted on the one side of the top of the male mold, and having an inclined top surface designed as an inclined guiding surface, a straight bar being protruded towards the male core from an end surface of the first sliding block and projected into the shaping cavity, the first sliding block defining an inserting space extending slantwise to penetrate therethrough; anda second sliding block slidably mounted on the inclined guiding surface of ...

Injection mold

Antagonism of the vip signaling pathway

Vasoactive intestinal peptide (vip) receptor antagonists

Disclosed are VIP-R antagonists for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP-R antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of treating subjects with cancer or infection with VIP-R antagonists or stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

Antagonism of the vip signaling pathway

Herein is provided a use of a vasoactive intestinal peptide antagonist for treatment of an active cytomegalovirus infection in a subject diagnosed with and exhibiting signs or symptoms of an active cytomegalovirus infection, wherein the vasoactive intestinal peptide antagonist comprises a peptide having a C-terminal amide and is optionally modified with hydrocarbon or polyethylene glycol groups and wherein the peptide has SEQ ID NO: 9, wherein X is M. Corresponding uses in reduction of an active cytomegalovirus infection are also provided.

System for issuing a plurality of near filed communication membership cards over the air

一種空中發行多張近場通訊會員卡系統，可將會員卡片資料寫入安裝於近場通訊(Near Field Communication，NFC)無線行動裝置內之安全晶片(Secure Element)或SIM卡之安全晶片，例如單線協定用戶識別模組(SWP SIM)之系統，利用此一會員卡管理平台，可發行一張以上會員卡片於一NFC無線行動裝置，結合此一NFC無線行動裝置之近場通訊能力，使用者只要用一NFC無線行動裝置即可攜帶多張非接觸式NFC會員卡片於身上，易於多張卡片之使用，且於NFC無線行動裝置上安裝會員卡管理員程式後可提供有效之會員卡片管理，與應用服務之提供。因每一會員卡之個人化資料皆存於安全晶片上，利用GlobalPlatform規範加密機制加以保護，所以有高安全保護，且安裝於安全晶片上之每一張卡片皆可獨立運作。

Mold

Mold

Integrated mobile electronic secretary system combined with near-field communication mechanism

Movable intervertebral filling piece device

Nail pole device for dynamically fixing spine

Métodos de tratamiento del cáncer y las enfermedades infecciosas mediante terapias celulares

Esta divulgación se refiere a composiciones y métodos para revertir la senescencia en células T interrumpiendo la señalización del péptido intestinal vasoactivo (VIP) y/o inhibiendo la señalización del inhibidor de fosfatidilinositol-3-quinasa (PI3 quinasa) y usos en el tratamiento del cáncer y las infecciones virales crónicas. En ciertas realizaciones, la divulgación contempla métodos para revertir la senescencia de las células T mezclando células T in vitro con un agente que evita que VIP interactúe con receptores de VIP y/o un inhibidor de PI3 quinasa. En ciertas realizaciones, la divulgación contempla la expansión de células T senescentes mezclándolas con un inhibidor de la quinasa PI3, un agente que bloquea VIP y la señalización del receptor de VIP, una enzima que degrada VIP y combinaciones de los mismos. (Traducción automática con Google Translate, sin valor legal)

Methods of treating cancer and infectious diseases using cell based therapies

This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signalling and/or inhibiting phosphatidylinositol- 3 -kinase (PI3 kinase) inhibitor signalling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signalling, a VIP degrading enzyme, and combinations thereof.

Vasoactive intestinal peptide (vip) receptor antagonists

Disclosed are VIP-R antagonists for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP-R antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of treating subjects with cancer or infection with VIP-R antagonists or stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

細胞ベースの治療法を用いて癌および感染性疾患を処置する方法

【課題】血管作動性腸管ペプチド（ＶＩＰ）シグナル伝達を中断し、かつ／またはホスファチジルイノシトール－３－キナーゼ（ＰＩ３キナーゼ）阻害剤のシグナル伝達を阻害することにより、Ｔ細胞の老化を反転させる組成物および方法、ならびに癌および慢性ウイルス感染の管理における使用を提供する。【解決手段】インビトロ細胞培養物組成物において、精製されたＴ細胞およびＶＩＰ受容体アンタゴニストならびにビーズまたは固体表面上に任意選択により固定化された抗ＣＤ３抗体および抗ＣＤ２８抗体を含むことを特徴とするインビトロ細胞培養物組成物とする。【選択図】図２

Expandable spine repairing apparatus

Vasoactive intestinal peptide (vip) receptor antagonists

Disclosed are VIP-R antagonists for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP-R antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of treating subjects with cancer or infection with VIP-R antagonists or stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

Compositions and uses of vasoactive intestinal peptide (vip) antagonists

This disclosure relates to VIP antagonist for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

防拔管鼻胃管裝置

一種防拔管鼻胃管裝置，包含一個管本體、一個拔管監測單元，以及一個訊號處理單元。該管本體具有一個主管壁，該主管壁界定出一個餵食通道，該拔管監測單元具有一個可分離地將該管本體固定在人體上的固定貼片，以及一個安裝在該固定貼片上的光感測模組，該光感測模組具有至少一個光感測器；該訊號處理單元具有一個處理器，該處理器具有一個與所述光感測器連接的拔管監測模組。前述結構的配合，可以監測該管本體是否脫落或者被拔除，藉以提高照顧病患的方便性。

Plastic injection mold

Methods of treating cancer and infectious diseases using cell based therapies

This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signalling and/or inhibiting phosphatidylinositol- 3 -kinase (PI3 kinase) inhibitor signalling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signalling, a VIP degrading enzyme, and combinations thereof.

Transaction in mobile card reader system using mobile phone and methods thereof

Methods of treating cancer and infectious diseases using cell based therapies

This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signalling and/or inhibiting phosphatidylinositol- 3 -kinase (PI3 kinase) inhibitor signalling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signalling, a VIP degrading enzyme, and combinations thereof.

Methods of treating cancer and infectious diseases using cell based therapies

This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signalling and/or inhibiting phosphatidylinositol- 3 -kinase (PI3 kinase) inhibitor signalling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signalling, a VIP degrading enzyme, and combinations thereof.

Compositions and uses of vasoactive intestinal peptide (vip) antagonists

Vasoactive intestinal peptide (vip) receptor antagonists

Disclosed are VIP-R antagonists for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP-R antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of treating subjects with cancer or infection with VIP-R antagonists or stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

Vasoactive intestinal peptide (vip) receptor antagonists

Disclosed are VIP-R antagonists for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP-R antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of treating subjects with cancer or infection with VIP-R antagonists or stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

Compositions and uses of vasoactive intestinal peptide (VIP) antagonists

This disclosure relates to VIP antagonist for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

Compositions and uses of vasoactive intestinal peptide (vip) antagonists

This disclosure relates to VIP antagonist for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

Injection mold

Injection mold

Methods of treating cancer and infectious diseases using cell based therapies

This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signalling and/or inhibiting phosphatidylinositol- 3 -kinase (PI3 kinase) inhibitor signalling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signalling, a VIP degrading enzyme, and combinations thereof.

多設備間資料異動非同步監控的方法

一種多設備間資料異動非同步監控的方法，應用於包含資料讀取執行模組、多執行緒、訊息佇列及計時模組之伺服器中，以非同步機制監控資料異動，提供客戶端終端設備資料異動詢問請求。

Sucking nipple connected with cover

Testing method for dynamic memory

Improvement of the socks hanger

Switching ware and mold having switching ware

Data refreshing method for data warehousing

Test device for finger power

The synchronous side core-pulling mechanism

茶香丸子結構

Injection mold

Disclosed is an injection mold, comprising a moving half, a fixed half and a plurality of bearing plates positioned therebetween. The moving half comprises a moving half plate and a moving half core positioned thereon. The fixed half comprises a fixed half plate and a fixed half cavity positioned thereon. The bearing plates are positioned on one of the fixed half plate and the moving half plate and a bearing surface is formed thereon. The moving half core and the fixed half cavity contact with each other partially to form an arrangement surface. With the bearing plates positioned therebetween, the bearing surface and the arrangement surface can undertake the closing mold pressure generated by an injection molding machine together for reducing the arrangement surface area. The molding is easy and cost drops to improve productivity. The closing mold balance of the entire injection mold can be preferably ensured.

一種複合層次脊椎椎間復位裝置

一種複合層次脊椎椎間復位裝置，植入於二椎體間，其包含有；一主載件，具有一中間層，及表面各一卡合層；多個卡合件，穩定連結於該等卡合層；其特徵在於：該中間層為一彈性模數介於2至22Gpa之高分子材料，接近該脊椎原12至18GPa，該等卡合件為一具優親骨細胞性、融合性、及可顯影性；該等卡合件緊密穩定於該卡合層，該裝置植入該等椎體間時，該卡合件直接接觸及以該卡合齒抵觸於該等相鄰椎體骨細胞上，及該中間層彈性模數相近，避免應力遮蔽效應。

Mold with slider structure

Test device for finger power

Mold

Mold assembly

Injection mold

Vasoactive intestinal peptide (vip) receptor antagonists

Disclosed are VIP-R antagonists for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP-R antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of treating subjects with cancer or infection with VIP-R antagonists or stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

Antagonism of the VIP Signaling Pathway

Inhibition of the VIP signaling pathway with VIP antagonist is contemplated. In certain embodiments, the disclosure relates to methods of enhancing the immune response to a cell therapy comprising administering a VIP antagonist to a subject in combination with a cell. In certain embodiments, the subject is diagnosed with leukemia or lymphoma, In certain embodiments, the cell is a blood cell, bone marrow cell, leukocyte, T-cell, natural killer cell, a hematopoietic stem cell, a G-CSF mobilized or non-mobilized blood mononuclear cell.

Methods of treating cancer and infectious diseases using cell based therapies

Methods of Treating Cancer and Infectious Diseases Using Cell Based Therapies

This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signalling and/or inhibiting phosphatidylinositol-3-kinase (PI3 kinase) inhibitor signalling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signalling, a VIP degrading enzyme, and combinations thereof.

Mold

Injection mold

Mold

Injection mold

Product mould having side undercut

Plastic injection mold

Mold

Plastic injection mold

System of automatically monitoring electronic billboard to immediately responding production abnormality and method thereof

A system of automatically monitoring an electronic billboard to immediately responding a production abnormality and a method thereof are disclosed. In the system, a monitoring device performs an image pattern analysis on a monitoring image to analyze at least one analysis area, and captures the at least one analysis area as a to-be-analyzed image; at least one image analysis method is set to transform the to-be-analyzed image into an image characteristic according to an image pattern of the to-be-analyzed image. When a comparison between the image characteristic and a preset characteristic indicates an abnormality, a monitoring device generates, records and transmits a warning message and/or issues an alarm, thereby achieving the technical effect of automatically monitoring the electronic billboard and immediately responding a production abnormality.

Three-plate mold

Mold

Wafer conversion tool of solar cell wafer carrying box

Methods of treating cancer and infectious diseases using cell based therapies

This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signalling and/or inhibiting phosphatidylinositol 3-kinase (P13 kinase) inhibitor signalling and uses in managing cancer and chronic viral infections. 5 In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a P13 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a P13 kinase inhibitor, an agent that block VIP and VIP receptor signalling, a VIP degrading enzyme, and combinations thereof.

Compositions and uses of vasoactive intestinal peptide (VIP) antagonists

This disclosure relates to VIP antagonist for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

Mold with ejector mechanism

Fixing device for spine nail